SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors react to the NOAA determination that the company's deep-seabed mining application is in full compliance, fueling community anticipation for accelerated permitting and long-term supply dominance. Investors are actively discussing the potential for a major deal with automotive manufacturers and tracking progress toward commercialization as a key catalyst for potential valuation re-rating.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares are surging after the company delivered a massive first-quarter beat, exceeding revenue and earnings estimates while providing strong guidance. The community remains highly focused on the stock's potential for a short squeeze and its long-term AI data licensing prospects, though some investors remain cautious about potential post-earnings volatility.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending after reporting explosive earnings that significantly exceeded estimates, driven by a massive surge in AI-related data center demand. While some investors are engaging in profit-taking following the stock's parabolic climb, the community is actively debating whether the company's strong guidance, record margins, and new multibillion-dollar share buyback program signal a sustained supercycle or an unsustainable bubble.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending as traders react to a milestone payment announcement and speculative short-squeeze activity surrounding its low float and upcoming annual meeting. Community sentiment is deeply divided between bulls targeting a breakout based on licensing momentum and critics highlighting risks from potential dilution and a proposed reverse stock split.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is drawing intense trader attention as a strong earnings beat, a massive share buyback authorization, and a dividend hike fuel optimism despite a modest post-market reaction. The community is actively debating the company's long-term leadership transition and whether these results can sustain momentum toward the 300 level.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox Corp. shares are trending after a significant post-earnings selloff, driven by a lower-than-expected full-year bookings outlook and engagement headwinds from new safety and age-verification protocols. While community sentiment is deeply polarized between those viewing the price drop as an attractive entry point for a platform with strong long-term engagement and those concerned about regulatory risks and predatory behavior, traders remain focused on the potential for volatility as the stock tests key support levels.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing extreme volatility and a massive short squeeze, driven by its ultra-low float and a borrow rate nearing 1,000%, which is forcing shorts to cover or face liquidation. Community sentiment is divided between retail bulls who are cheering the parabolic price action and skeptical traders warning of a potential rug-pull due to the company's history of reverse splits and weak fundamentals.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is currently experiencing extreme volatility driven by a massive retail-led short squeeze and heightened interest in its role as a key supplier for AI data center infrastructure. The community is sharply divided, with bulls pointing to the company's critical InP substrate technology as a long-term catalyst, while vocal bears argue the stock is a severely overvalued "pump and dump" scheme fueled by excessive speculation and disconnect from fundamental earnings.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is experiencing heightened volatility and intense community discussion following a significant workforce restructuring and strategic pivot toward AI and enterprise sales. Investors and market participants are actively debating the stock's long-term viability, weighing the company's strong cloud execution against widespread concerns about potential AI disruption and the stock's recent removal from the Nasdaq-100.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as investors weigh a significant earnings beat against concerns over potential future dilution, highlighted by a freshly filed shelf offering and a restructured DOE loan. The community remains sharply divided, with bulls pointing to the long-term potential of the R2 production ramp and strategic partnerships, while bears emphasize ongoing cash burn, executive compensation, and the heavy reliance on Amazon for revenue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates

Aligos shares rise after China licensing deal for HBV drug; milestones, trial updates, and technical levels shape investor outlook.read more...

<ul class="summary-bullets"><li>Pevifoscorvir Sodium is an experimental drug that is currently in a mid-stage clinical trial, with further results expected in 2026 and 2027.</li><li>Aligos will receive an upfront payment of $25 million and could earn up to $420 million in milestone payments.</li><li>After the deal, the biotech firm expects its current cash, cash equivalents, and investments to support operations into the fourth quarter of 2026.</li></ul>Shares of&nbsp;Aligos&nbsp;Therapeutics (ALGS) surged nearly 20% in pre-market trading on Thursday, after the biotech firm announced a licensing deal with Xiamen Amoytop Biotech to develop and commercialize its hepatitis B drug candidate, Pevifoscorvir Sodium, in Greater China.If the pre-market levels hold, <a href="https://stocktwits.com/symbol/ALGS">ALGS shares</a> would record their biggest intraday gains since May 12, 2025.Pevifoscorvir Sodium is an experimental drug being developed to treat chronic hepatitis B by targeting different stages of the virus. The drug is currently in a mid-stage clinical trial, with more results expected in 2026 and 2027.<h2 class="st-heading-2">Aligos Could Earn Up To $420 Million</h2>Under the agreement, Aligos will receive $25 million upfront and could earn up to $420 million in milestone payments, along with royalties on future sales. Amoytop will fund development and handle commercialization across the region, including Mainland China, Hong Kong, Taiwan, and Macau. Aligos will retain rights to the drug in other global markets, including the U.S., Europe, South Korea, and Japan.As a result of this agreement, Aligos expects its current cash, cash equivalents, and investments to support operations into the fourth quarter (Q4) of 2026.Aligos said that combining Pevifoscorvir Sodium with Amoytop’s Pegbing could yield better treatments.“Additionally, we believe that combining Pevifoscorvir Sodium with Amoytop’s drug PEGBING®, along with our ongoing ASO collaboration, will enable differentiated combination regimens and more personalized treatment approaches for patients with chronic HBV infection across Greater China,” said Lawrence Blatt, Chairman, President, and CEO of Aligos Therapeutics.The deal targets a large market, with more than 90 million people affected by chronic hepatitis B in Greater China.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.One user said the stock is retesting its resistance levels and sees potential upside beyond $12.20.<stembedurl>https://stocktwits.com/YouVSYou/message/650443684</stembedurl>Another user noted that despite a “relatively small” upfront fee, it is sufficient to extend the company’s runway.<stembedurl>https://stocktwits.com/aletz/message/650441794</stembedurl>Year-to-date, the stock has lost around 25%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

This Micro Cap Biotech Stock Is Tracking Its Biggest Intraday Gains In 11 Months – Here’s Why A China Deal Has Retail Buzzing

Aligos Therapeutics announced a licensing deal with Xiamen Amoytop Biotech to develop and commercialize its hepatitis B drug candidate in Greater China.

This Micro Cap Biotech Stock (ALGS) Is Tracking Its Biggest Intraday Gains In 11 Months

Equity

Aligos Therapeutics Earnings Report: Q4 Overview

A Peek at Aligos Therapeutics's Future Earnings

Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% - Time to Sell?

Aligos Therapeutics (NASDAQ:ALGS) Trading Down 4.5% - Here's What Happened...

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Current Price	$5.96
Prev Close	$5.99
Open	$5.96
Dividend Yield	0.00%
50-Day Moving Average	$7.13
Beta	1.86
Avg. Volume	43,692.95
PE Ratio	-0.70

52-Week High	$13.69
52-Week Low	$4.20
Market Capitalization	$37.06M
EPS (Annual)	-$2.45
Price to Book	0.69
Revenue Per Employee	$26,658.54

ALGS
Aligos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALGS News

ALGSAligos Therapeutics Inc